Brief communication: efficacy and safety of the dolutegravir/lamivudine dual therapy in antiretroviral treatment-experienced Chinese people living with HIV

Brief communication: efficacy and safety of the dolutegravir/lamivudine dual therapy in antiretroviral treatment-experienced Chinese people living with HIV

Abstract This study aimed to evaluate the efficacy and safety of dolutegravir plus lamivudine (DTG/3TC) in antiretroviral treatment (ART)-experienced people living with HIV (PLWH). A total of 303 PLWH in Shanghai, China, who switched from triple ART to DTG/3TC between January 2019 and June 2022, wit...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Zhenyan Wang, Junyang Yang, Lin Wang, Jiangrong Wang, Yinzhong Shen, Jun Chen, Tangkai Qi, Jianjun Sun, Wei Song, Yang Tang, Shuibao Xu, Li Liu, Renfang Zhang
Aineistotyyppi: Artikkeli
Kieli:English
Julkaistu: BMC 2024-11-01
Sarja:AIDS Research and Therapy
Aiheet:
HIV
Dolutegravir
Lamivudine
Antiretroviral
Linkit:https://doi.org/10.1186/s12981-024-00680-x

Internet

https://doi.org/10.1186/s12981-024-00680-x

Samankaltaisia teoksia